[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342868-105":59,"doc-detail-342868-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preliminary-outcomes-of-boron-neutron-capture-therapy-for-head-and-neck-cancers-as-a-treatment-covered-by-public-health-insurance-system-in-japan-real-world-experiences-over-a-2-year-period","Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan - Real-world experiences over a 2-year period","","Purpose: Since June 2020, boron neutron capture therapy (BNCT) has been covered by Japan’s health insurance for locally advanced or recurrent unresectable head and neck cancers. The study evaluated clinical outcomes under insured practice and examined BNCT’s role among standard treatment options. Materials and Methods: A retrospective analysis used Kansai BNCT Medical Center data from June 2020 to May 2022. Objective responses used RECIST v1.1, adverse events used CTCAE v5.0, with survival analyses and factor exploration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preliminary-outcomes-of-boron-neutron-capture-therapy-for-head-and-neck-cancers-as-a-treatment-covered-by-public-health-insurance-system-in-japan-real-world-experiences-over-a-2-year-period/342868/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preliminary-outcomes-of-boron-neutron-capture-therapy-for-head-and-neck-cancers-as-a-treatment-covered-by-public-health-insurance-system-in-japan-real-world-experiences-over-a-2-year-period/342868.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of assessing BNCT in Japan’s health insurance setting?","Question",{"text":112,"@type":113},"To evaluate clinical outcomes of BNCT as an insured treatment and clarify its role among standard modalities for locally advanced or recurrent unresectable head and neck cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were objective response and adverse events evaluated?",{"text":117,"@type":113},"Objective response used RECIST version 1.1, and adverse events were assessed using CTCAE version 5.0.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were reported for the 69-patient cohort over about 15 months median observation?",{"text":121,"@type":113},"The objective response rate was 80.5%, with 1-year locoregional control 57.1%, progression-free survival 42.2%, and overall survival 75.4%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342868,1790839760,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","DOI: 10. 1002/cam4 .7250  \nRESEAR CH ARTICLE  \nPreliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan: Real-world experiences over a 2-year period  \nSatoshi Takeno1,2  | Yuki Yoshino1,2 | Teruhito Aihara2,3 | Masaaki Higashino3 | Yasukazu Kanai2,4 | Naonori Hu2,5 | Ryo Kakino2 | Ryo Kawata3 |  \nKeiji Nihei1,2 | Koji Ono2,4  \n1Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan  \n2Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka, Japan  \n3Department of Otorhinolaryngology – Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan  \n4BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Osaka, Japan  \n5Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan  \nCorrespondence  \nSatoshi Takeno, Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569- 8686, Japan.  \nEmail: [satoshi.takeno@ompu.ac.jp](satoshi.takeno@ompu.ac.jp)  \nFunding information  \nJapan Society for the Promotion of Science, Grant/Award Number:  \nJP23K14878  \nAbstract  \nPurpose: Since June 2020, boron neutron capture therapy (BNCT) has been a health care service covered by health insurance in Japan to treat locally advanced or recurrent unresectable head and neck cancers. Therefore, we aimed to assess the clinical outcomes of BNCT as a health insurance treatment and explore its role among the standard treatment modalities for head and neck cancers. Materials and Methods: We retrospectively analyzed data from patients who were treated using BNCT at Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, between June 2020 and May 2022. We assessed objective response rates based on the Response Evaluation Criteria in Solid Tumors version 1.1, and adverse events based on the Common Terminology Criteria for Adverse Events, version 5.0. Additionally, we conducted a survival analysis and explored the factors that contributed to the treatment results.  \nResults: Sixty-nine patients (72 treatments) were included in the study, with a median observation period of 15 months. The objective response rate was 80.5%, and the 1-year locoregional control, progression-free survival, and overall survival rates were 57. 1%(95% confidence interval [CI]: 43.9%–68.3%), 42.2%(95% CI: 30. 1%–53.8%), and 75.4%(95% CI: 62.5%–84.5%), respectively. Locoregional control was significantly longer in patients with earlier TNM staging and no history of chemotherapy. Conclusions: BNCT may be an effective treatment option for locally advanced or recurrent unresectable head and neck cancers with no other definitive therapies. If definitive surgery or radiation therapy are not feasible, BNCT should be considered at early disease stages.  \nKEYWORDS  \nboron neutron capture therapy, boron, head and neck cancer, re-irradiation, radiation therapy  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \n1 | INTRODUCTION  \nBoron neutron capture therapy (BNCT) is a treatment in which compounds containing boron (10B) are incorporated into tumors followed by subsequent irradiation with thermal neutrons.1 This causes a boron neutron capture reaction (10B(n, α)7Li) within the cells that have incorporated the boron compounds, resulting in high-linear energy transfer (LET) particles that destroy the tumor. These high-LET particles have a range of \u003C10μm, which is shorter than the diameter of a single cell. Therefore, they can selectively destroy tumor cells while minimizing damage to neighboring cells, even if the tumor is invasive and actively spreading.2,3  \nConsidering these mechanism","cbCairbE8sLqt6NF","https://ap.wps.com/l/cbCairbE8sLqt6NF","pdf",1957061,12,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction\n## Mechanism of BNCT\n## Key boron compounds\n## Dose evaluation\n## BNCT history and development","[{\"question\":\"What was the purpose of assessing BNCT in Japan’s health insurance setting?\",\"answer\":\"To evaluate clinical outcomes of BNCT as an insured treatment and clarify its role among standard modalities for locally advanced or recurrent unresectable head and neck cancers.\"},{\"question\":\"How were objective response and adverse events evaluated?\",\"answer\":\"Objective response used RECIST version 1.1, and adverse events were assessed using CTCAE version 5.0.\"},{\"question\":\"What outcomes were reported for the 69-patient cohort over about 15 months median observation?\",\"answer\":\"The objective response rate was 80.5%, with 1-year locoregional control 57.1%, progression-free survival 42.2%, and overall survival 75.4%.\"}]","Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan - Real-world experiences over a 2-year period | PDF",1790048489,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1938265a7b6f0c0f62deef316f3ef93b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a53f598d99390a8485343edb6e2658a6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb408ffec121627b56f3a26791c15ccf.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32821396da58d10b086a28abb9f5ae7d.webp",980,1287]